Weight loss | Jotup

Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024

Retrieved on:

星期三, 五月 8, 2024

Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.

Key Points:

Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.
The Cancer Cachexia market refers to the segment of the healthcare industry focused on addressing the multifaceted challenges associated with cachexia in cancer patients.
A report from Custom Market Insights projects that the global Cancer Cachexia Market is expected to record a CAGR of 5.1% from 2024 to 2033.
In 2024, the market size is projected to reach a valuation of USD 3.3 Billion.

ALTIMMUNE, INC. (NASDAQ: ALT) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Altimmune, Inc.

Retrieved on:

星期二, 五月 7, 2024

Semaglutide, News, Complaint, Weight loss, Obesity, Action Replay, District court, Defendant, Court, Hepatology, Kerrisdale, Advertising, Security (finance)

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, inclusive (the “Class Period”).

Key Points:

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, inclusive (the “Class Period”).
If you purchased or acquired Altimmune securities, and/or would like to discuss your legal rights and options please visit Altimmune, Inc.
Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

FibroGen Reports First Quarter 2024 Financial Results

Retrieved on:

星期一, 五月 6, 2024

Expect approval decision for roxadustat in chemotherapy-induced anemia (CIA) in China in the second half of 2024.

Key Points:

Expect approval decision for roxadustat in chemotherapy-induced anemia (CIA) in China in the second half of 2024.
Total revenue for the first quarter of 2024 was $55.9 million, as compared to $36.2 million for the first quarter of 2023, an increase of 55% year over year.
At March 31, 2024, FibroGen reported $214.7 million in cash - defined as cash, cash equivalents, investments, and accounts receivable.
FibroGen will host a conference call and webcast today, Monday, May 6, 2024, at 5:00 PM Eastern Time to discuss financial results and provide a business update.

EUDA Health Expands into Direct Selling Holistic Wellness Products with Acquisition of CK Health

Retrieved on:

星期一, 五月 6, 2024

Digestion, Genetics, Inflammation, Neuroscience, Weight loss, DNA, Pain management, Acquisition, CK, Bioenergy

SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it will acquire CK Health Plus Sdn Bhd (“CK Health”), a direct seller of holistic wellness consumer products in Malaysia.

Key Points:

SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it will acquire CK Health Plus Sdn Bhd (“CK Health”), a direct seller of holistic wellness consumer products in Malaysia.
Established in Malaysia in 2023, CK Health is a direct seller of holistic wellness consumer products through its online platform and member network.
CK Health’s products leverage non-invasive therapies to make holistic healthcare accessible for everyone using advanced technologies.
Through CK Health, EUDA will license bioenergy cabins to partners such as spas, beauty salons, and confinement centers and will distribute Yoroyal’s consumer products through direct selling, e-commerce platforms, and retail outlets.

Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

Retrieved on:

星期一, 五月 6, 2024

POMC, FDA, Shanda, PES, Body mass index, Food, New Drug Application, BMI, LEPR, Weight loss, BBS, Bardet–Biedl syndrome, MC4R, Obesity, Patient, Rhythm, Annual general meeting, Proopiomelanocortin, Pharmaceutical industry

BOSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Company delivered three presentations – one oral and two posters – at The Pediatric Endocrine Society’s (PES) Annual Meeting held May 2-5, 2024 in Chicago, IL.

Key Points:

BOSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Company delivered three presentations – one oral and two posters – at The Pediatric Endocrine Society’s (PES) Annual Meeting held May 2-5, 2024 in Chicago, IL.
In the oral presentation, Rhythm showcased data that was previously announced on December 6, 2023, from its 52-week, Phase 3 pediatrics trial in patients between the ages of 2 and younger than 6 years (N=12) with Bardet-Biedl syndrome (BBS) or obesity due to proopiomelanocortin (POMC) or leptin receptor (LEPR) deficiency.
Treatment with setmelanotide achieved the primary endpoint with a 3.04 mean reduction in BMI-Z score (a measure of body mass index deviations from what is considered normal) and 18.4 percent mean reduction in body mass index (BMI).
Rhythm also presented two additional poster presentations at PES 2024:

Together by Renee Launches Innovative Find My Meds Feature to Ensure Continuous Access to Essential GLP-1 and Other Medications

Retrieved on:

星期二, 五月 7, 2024

Health, Technology, Telemedicine, Virtual Medicine, Software, Artificial Intelligence, Pharmaceutical, Pharmacy, AI, Diabetes, Hand, Weight loss, Prescription, Patient, Mental health, Multimedia, Ageing

Together by Renee , the leading AI-based health assistant, announced the launch of a groundbreaking new feature in its platform: Find My Meds.

Key Points:

Together by Renee , the leading AI-based health assistant, announced the launch of a groundbreaking new feature in its platform: Find My Meds.
The introduction of Find My Meds closely follows the ranking of Together by Renee as No.
10 in the wellness and personal care category on Fast Company’s 2024 Most Innovative Companies list.
(Graphic: Business Wire)
Find My Meds leverages Together by Renee’s advanced AI technology to ensure that patients receive their necessary medications without interruption.

Evidation Shares Real-World Data on GLP-1 Use and Social Determinants of Health at ISPOR 2024

Retrieved on:

星期一, 五月 6, 2024

Current GLP-1 users were more likely to have private insurance and to be targeting more significant weight loss.

Key Points:

Current GLP-1 users were more likely to have private insurance and to be targeting more significant weight loss.
Social Determinants of Health Associated with Delayed Medical Care in an Online Health Community (#EPH199) illuminates critical and persistent barriers to timely medical care from a survey of 203,486 US adults.
Almost 5 million Members strong, Evidation rewards users for engaging in healthy activities and contributing to health research.
Using Evidation, health researchers can comprehensively characterize and measure disease onset and progression, treatment impact, quality of life, and social determinants of health across diverse populations over longer observation periods.

Promino Nutritional Sciences and Dr. Patrick Gunning to Begin Preclinical Studies Focused on Targeted Nutritional Supplementation for Cancer Patients

Retrieved on:

星期三, 五月 8, 2024

University, Cancer, Facial muscles, Professor, OTC, Weight loss, Doctor of Philosophy, University of Toronto, Patient, Medicinal chemistry, Fatigue, Medicine, Genome, Neoplasm, Prevalence, Medical imaging

Dr. Gunning will be joining the Company as a special advisor on various preclinical studies over the next 12 months.

Key Points:

Dr. Gunning will be joining the Company as a special advisor on various preclinical studies over the next 12 months.
Dr. Gunning has published over 130 papers, won over 20 research awards, including being named in Canada's Top 40 under 40.
"The health care industry has been moving toward personalized medicine since the mapping of the genome," stated Vito Sanzone, CEO of Promino Nutritional Sciences.
We couldn't be more pleased to have the calibre of Professor Gunning involved in this project."

Huawei's Innovative Product Launch Event was Held in Dubai, Releasing Multiple New Blockbuster Products

Retrieved on:

星期二, 五月 7, 2024

Right after this product launch, we're holding another event here in Dubai, entitled 'A Heartwarming World—12 Years of Huawei Photography'.

Key Points:

Right after this product launch, we're holding another event here in Dubai, entitled 'A Heartwarming World—12 Years of Huawei Photography'.
The new MateBook X Pro and MatePad 11.5"S: Tools for joyful creation
Last year, on December 12, Huawei held a product launch event in Dubai, centred around the concept "Creation of Beauty".
In addition, the Innovative Product Launch included the unveiling of the FreeBuds 6i, with enhanced noise cancellation capabilities.
In the days after the product launch event, from May 8-10, Huawei is holding an exhibition entitled "A Heartwarming World—12 Years of Huawei Photography" at Concrete on Alserkal Avenue in Dubai.

Huawei's Innovative Product Launch Event was Held in Dubai, Releasing Multiple New Blockbuster Products.

Retrieved on:

星期二, 五月 7, 2024

Right after this product launch, we're holding another event here in Dubai, entitled 'A Heartwarming World—12 Years of Huawei Photography'.

Key Points:

Right after this product launch, we're holding another event here in Dubai, entitled 'A Heartwarming World—12 Years of Huawei Photography'.
The new MateBook X Pro and MatePad 11.5"S: Tools for joyful creation
Last year, on December 12, Huawei held a product launch event in Dubai, centred around the concept "Creation of Beauty".
In addition, the Innovative Product Launch included the unveiling of the FreeBuds 6i, with enhanced noise cancellation capabilities.
In the days after the product launch event, from May 8-10, Huawei is holding an exhibition entitled "A Heartwarming World—12 Years of Huawei Photography" at Concrete on Alserkal Avenue in Dubai.